Showing 9,301 - 9,320 results of 32,204 for search '(( a step decrease ) OR ( 50 ((((mean decrease) OR (nn decrease))) OR (a decrease)) ))', query time: 1.39s Refine Results
  1. 9301

    Study characteristics. by Zhuoyang Xia (21354186)

    Published 2025
    “…The DerSimonian–Laird random-effects model and the Cochrane Collaboration’s risk of Bias Tool were used for analysis and risk of bias assessment.</p><p>Results</p><p>A total of 12 RCTs involving 18,086 patients were finally included. …”
  2. 9302

    Flowchart of literature retrieval. by Zhuoyang Xia (21354186)

    Published 2025
    “…The DerSimonian–Laird random-effects model and the Cochrane Collaboration’s risk of Bias Tool were used for analysis and risk of bias assessment.</p><p>Results</p><p>A total of 12 RCTs involving 18,086 patients were finally included. …”
  3. 9303

    Data extraction. by Zhuoyang Xia (21354186)

    Published 2025
    “…The DerSimonian–Laird random-effects model and the Cochrane Collaboration’s risk of Bias Tool were used for analysis and risk of bias assessment.</p><p>Results</p><p>A total of 12 RCTs involving 18,086 patients were finally included. …”
  4. 9304

    Cochrane Collaboration’s risk of bias tool. by Zhuoyang Xia (21354186)

    Published 2025
    “…The DerSimonian–Laird random-effects model and the Cochrane Collaboration’s risk of Bias Tool were used for analysis and risk of bias assessment.</p><p>Results</p><p>A total of 12 RCTs involving 18,086 patients were finally included. …”
  5. 9305

    Silencing in GFP-expressing THP-1 cells. (A) by Breanne Landry (138815)

    Published 2012
    “…<p>The cell counts as measured by flow cytometry (expressed as a percentage of non-treated cells). (<b>B</b>) Silencing was assessed after 3 days of siRNA treatment (50 nM) and expressed as decrease in mean GFP fluorescence or decrease in GFP-positive cells. …”
  6. 9306
  7. 9307

    ßNGF expression. by Cédric Mauprivez (819048)

    Published 2015
    “…When mast cells are activated, their granule content is released outside the cell, thus the immunostaining for the marker progressively decreases within the cell. Magnification bars, <b>A</b> to <b>E</b>: 50 μm; <b>F</b> to <b>I</b>: 10 μm. …”
  8. 9308

    Untargeted Urinary Proteomics Uncovers Nephroprotective and Systemic Adaptations after Obesity Surgery-Induced Weight Loss by Pedro R. Pereira (6016460)

    Published 2025
    “…A decrease in inflammation protein markers (α-1-acid glycoproteins), alongside an increase in proteins associated with immune modulation and oxidative stress protection (dipeptidase 1, heat shock cognate 71 kDa protein) were observed. …”
  9. 9309

    Change in Adverse Events After Enrollment in the National Surgical Quality Improvement Program: A Systematic Review and Meta-Analysis by Joshua Montroy (848622)

    Published 2016
    “…Studies evaluating other adverse events noted decreased incidence following NSQIP participation and implementation of a formal quality improvement program.…”
  10. 9310

    DOT or SAT for Rifampicin-resistant tuberculosis? A non-randomized comparison in a high HIV-prevalence setting by Erika Mohr (3331566)

    Published 2017
    “…</p><p>Conclusion</p><p>The introduction of SAT during the continuation phase of RR-TB treatment does not adversely affect final RR-TB treatment outcomes in a high TB and HIV-burden setting. This differentiated, patient-centred model of care could be considered in RR-TB programmes to decrease the burden of DOT on patients and health facilities.…”
  11. 9311
  12. 9312
  13. 9313

    A Novel Function for Kojic Acid, a Secondary Metabolite from <i>Aspergillus</i> Fungi, as Antileishmanial Agent by Ana Paula D. Rodrigues (534028)

    Published 2014
    “…KA (50 μg/mL) was found to decrease the growth by 62% (IC<sub>50</sub> 34 μg/mL) and 79% (IC<sub>50</sub> 27.84 μg/mL) of promastigotes and amastigotes <i>in vitro</i>, respectively. …”
  14. 9314
  15. 9315

    Test with a separable stochastic subsystem. by James C. Schaff (3396203)

    Published 2016
    “…(B) The multi-trial mean, , converges to an exact expectation value with the increasing number of trials and decreasing time step <i>Δt</i> (data points for <i>Δt</i> = 0.02 s, 0.006 s, and 0.002 s are shown as triangles, squares, and circles, respectively). …”
  16. 9316

    Model for how Rdh54 alters HR pathway choice. by Margaret Keymakh (13783384)

    Published 2022
    “…Rdh54 slows the rate of Rad51 clearance leading to an increase in potential template switching, or a decrease in BIR initiation. Rdh54 translocation can then regulate NCO/CO outcomes through movement away from the D-loop. …”
  17. 9317
  18. 9318
  19. 9319

    Table_1_Immunotherapy With Recombinant Alt a 1 Suppresses Allergic Asthma and Influences T Follicular Cells and Regulatory B Cells in Mice.docx by Juan Liu (6492)

    Published 2021
    “…</p>Methods<p>We synthesized and purified rAlt a 1. Alternaria-sensitized and challenged mice received subcutaneous immunotherapy (SCIT) with four different rAlt a 1 dosages (5, 50, 100, and 150 µg) or PBS only. …”
  20. 9320

    Image_1_Immunotherapy With Recombinant Alt a 1 Suppresses Allergic Asthma and Influences T Follicular Cells and Regulatory B Cells in Mice.tif by Juan Liu (6492)

    Published 2021
    “…</p>Methods<p>We synthesized and purified rAlt a 1. Alternaria-sensitized and challenged mice received subcutaneous immunotherapy (SCIT) with four different rAlt a 1 dosages (5, 50, 100, and 150 µg) or PBS only. …”